”Transforming gene therapy with an advanced AAV delivery platform“ KU Leuven's Trellis Research Group, headed by Prof. Dr. Els Henckaerts, developed an innovative process that equips rAAV vectors with molecules that accurately target them towards their intended locations. This advancement enables more efficient delivery and can help future rAAV gene therapies to have fewer side effects Co-founded with General Inception, KU-LRD and Gemma Frisius Fund in 2023,Tavira Therapeutics is currently in the process of securing additional funding in order to expand the initial proof of principle, grow the team, and ultimately deliver a more efficient and effective therapeutic solution to patients. The appointment of Bob Smith as an independent Chairman further bolsters the already robust team at Tavira. Wishing all the best to Tavira !!! #Tavira Therapeutcs #KU Leuven LRD #Bob Smith
We are thrilled to announce that Tavira Therapeutics has successfully closed our pre-seed funding round! With this funding round we also welcome Bob Smith to the board as our Independent Chairman. A huge thank you to our investors- General Inception and Gemma Frisius Fund and supporters KU Leuven Research & Development (LRD) and the Trellis lab for believing in our vision. Your trust and commitment empower us to innovate and drive meaningful change in the AAV gene therapy field. Stay tuned for more updates as we embark on this exciting journey. Together, we’re building something extraordinary! General Inception KU Leuven Research & Development #FundingAnnouncement #AAV #GeneTherapy #Spinout #Innovation #Capsid #KUL #Leuven https://lnkd.in/eRvrJCRS